bf/NASDAQ:AVXL_icon.jpeg

NASDAQ:AVXL

Anavex Life Sciences Corp.

  • Stock

USD

Last Close

7.40

06/11 22:14

Market Cap

391.04M

Beta: 0.75

Volume Today

740.90K

Avg: 1.09M

PE Ratio

−8.31

PFCF: −16.52

OverviewFinancialsAPI

    Description

    Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II c...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.2-0.15-0.1-0.052018-12-122020-09-292022-08-092024-04-082024-12-23

    Revenue (Estimate*)

    0.000.000.010.010.012018-12-122020-09-292022-08-092024-04-082024-12-23

    *Estimate based on analyst consensus